CKPT - Checkpoint Therapeutics Inc. (CKPT) Investigation: Bronstein Gewirtz & Grossman LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

NEW YORK, NY / ACCESSWIRE / December 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT). Investors who purchased Checkpoint securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ckpt.

The investigation concerns whether Checkpoint has violated federal securities laws.

Investigation Details:

On December 18, 2023, Checkpoint issued a press release "announc[ing] that the U.S. Food and Drug Administration (‘FDA') has issued a complete response letter (‘CRL') for the cosibelimab biologic license application (‘BLA') for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (‘cSCC') who are not candidates for curative surgery or radiation. The CRL only cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party contract manufacturing organization as approvability issues to address in a resubmission." The Company's President and Chief Executive Officer stated that "we believe we can address the feedback in a resubmission to enable marketing approval in 2024". On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

What's Next?

If you are aware of any facts relating to this investigation or purchased Checkpoint securities, you can assist this investigation by visiting the firm's site: bgandg.com/ckpt. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC